Basic fibroblast growth factor (bFGF): Mitogenic activity and binding sites in human breast cancer

Peyrat, Jean‐Philippe; Bonneterre, Jacques; Hondermarck, Hubert; Hecquet, B; Adenis, Antoine; Louchez, M M; Lefèbvre, Jean Louis; Boilly, B; Demaille, A

doi:10.1016/0960-0760(92)90191-k

Cited by 31 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FGF2 is a growth factor that induces proliferation in cells expressing FGFR [38]. In this case, the ability of the FGF2 domain to bind FGFR is critical to our goal of targeting cells over-expressing FGFR.…”

Section: Discussionmentioning

confidence: 99%

Recombinant polymer‐protein fusion: a promising approach towards efficient and targeted gene delivery

Hatefi

Megeed

Ghandehari

2006

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Recombinant polymer‐protein fusion: a promising approach towards efficient and targeted gene delivery

Hatefi

Megeed

Ghandehari

2006

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

“…The disruption of the vascular basement membrane may facilitate extravasation of endothelial cells, leading to the formation of neovascular sprouts, as well as intravasation of tumour cells into the vessels. The overexpression of the members of VEGF, FGF and IGF families, as well as their receptors, has been reported in a significant percentage of breast tumours (Peyrat et al, 1992;Brown et al, 1995;Yee, 1998). Moreover, the overexpression of human epidermal growth factor receptor-2 (ErbB-2/HER-2), which is associated with poor survival in several human malignancies including breast cancers, is closely correlated with increased angiogenesis and expression of VEGF (reviewed in Kumar and Yarmand-Bagheri, 2001).…”

mentioning

confidence: 99%

Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers

et al. 2004

View full text Add to dashboard Cite

The overexpression of angiogenic factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and insulin-like growth factors (IGFs) plays a role in the migration and proliferation of endothelial cells in many cancers. Consequently, we investigated the effects of bombesin/gastrin-releasing peptide (GRP) antagonists on the expression of these angiogenic factors, the activities of matrix metalloproteinases (MMPs)-2 and -9, as well as the vascular density in MDA-MB-435 human oestrogenindependent breast cancers. Nude mice bearing orthotopic xenografts of MDA-MB-435 breast cancers were treated with bombesin/ GRP antagonists for 6 weeks. Daily administration of 20 mg of RC-3095 or 10 mg of RC-3940-II significantly decreased the weight of MDA-MB-435 cancers by 44 and 53%, respectively. The inhibition of tumour growth was associated with a substantial reduction in the expression of mRNA and protein levels of basic fibroblast growth factor (bFGF), IGF-II and VEGF-A in the tumours. Both bombesin/GRP antagonists significantly decreased the vessel density of the tumours by about 37%, as shown by immunohistochemical detection of vessels on tumour slides. Gelatinolytic activities, detected by zymography, revealed a 33 -46% reduction in MMP-9 activity after the treatment with either antagonist. In vitro studies revealed that MDA-MB-435 cells secrete bFGF, IGF-II and VEGF-A, and the secretion of these factors is inhibited by RC-3095 and RC-3940-II. This study demonstrates the antiangiogenic effect of bombesin/GRP antagonists RC-3095 and RC-3940-II, and underscores their possible therapeutic application for treatment of breast cancers.

show abstract

“…This repair function may be mobilized in the presence of certain pathological conditions, for instance, diseases of the retina, muscular dystrophy, rheumatoid arthritis, and Alzheimer's disease (reviewed in reference 13). Furthermore, it appears that inappropriate or altered expression of FGFs and their receptors occurs in the presence of a variety of cancers, including many common carcinomas (1,2,10,18,19,27,28,32,33,43,50).…”

mentioning

confidence: 99%

FGF-18, a Novel Member of the Fibroblast Growth Factor Family, Stimulates Hepatic and Intestinal Proliferation

Qiu

Wang

et al. 1998

Molecular and Cellular Biology

131

View full text Add to dashboard Cite

The fibroblast growth factors (FGFs) play key roles in controlling tissue growth, morphogenesis, and repair in animals. We have cloned a novel member of the FGF family, designated FGF-18, that is expressed primarily in the lungs and kidneys and at lower levels in the heart, testes, spleen, skeletal muscle, and brain. Sequence comparison indicates that FGF-18 is highly conserved between humans and mice and is most homologous to FGF-8 among the FGF family members. FGF-18 has a typical signal sequence and was glycosylated and secreted when it was transfected into 293-EBNA cells. Recombinant murine FGF-18 protein (rMuFGF-18) stimulated proliferation in the fibroblast cell line NIH 3T3 in vitro in a heparan sulfate-dependent manner. To examine its biological activity in vivo, rMuFGF-18 was injected into normal mice and ectopically overexpressed in transgenic mice by using a liver-specific promoter. Injection of rMuFGF-18 induced proliferation in a wide variety of tissues, including tissues of both epithelial and mesenchymal origin. The two tissues which appeared to be the primary targets of FGF-18 were the liver and small intestine, both of which exhibited histologic evidence of proliferation and showed significant gains in organ weight following 7 (sometimes 3) days of FGF-18 treatment. Transgenic mice that overexpressed FGF-18 in the liver also exhibited an increase in liver weight and hepatocellular proliferation. These results suggest that FGF-18 is a pleiotropic growth factor that stimulates proliferation in a number of tissues, most notably the liver and small intestine.

show abstract

Basic fibroblast growth factor (bFGF): Mitogenic activity and binding sites in human breast cancer

Cited by 31 publications

References 21 publications

Recombinant polymer‐protein fusion: a promising approach towards efficient and targeted gene delivery

Recombinant polymer‐protein fusion: a promising approach towards efficient and targeted gene delivery

Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers

FGF-18, a Novel Member of the Fibroblast Growth Factor Family, Stimulates Hepatic and Intestinal Proliferation

Contact Info

Product

Resources

About